Federal State Unitary Enterprise "Moscow Endocrine Plant" (hereinafter referred to as the Enterprise), which is subordinate to the Ministry of Industry and Trade of Russia, in accordance with the order of the Government of the Russian Federation dated April 17, 2020, No. 1059-r, in accordance with the established procedure, carried out the purchase, import and delivery to medical institutions of the drug "Oncaspar" not registered in the Russian Federation (international non-proprietary name of Pegaspargaz).
This drug was imported in the amount of 1,500 packs calculated by the Ministry of Health of Russia to provide needy children suffering from acute lymphoblastoma leukemia (malignant tumor of the hematopoietic system) from 59 constituent entities of the Russian Federation.
The purchase and import of Oncaspar into the Russian Federation was carried out in three stages – 500 packages each in June, August and November this year.
The first two batches of the drug "Oncaspar" as soon as possible after import were delivered to the medical institutions of the constituent entities of the Russian Federation determined by the Ministry of Health of Russia to provide medical care to children in a hospital. The delivery of the third batch of the drug to the constituent entities of the Russian Federation was completed on November 27, 2020. In total, the delivery was carried out to 69 medical institutions in the country.
Thus, the well-coordinated work of the Government of the Russian Federation, federal executive authorities and the Federal State Unitary Enterprise “Moscow Endocrine Plant”, helped to implement the socially important task of providing the drug “Oncaspar” to children in need of it for medical reasons in the constituent entities of the Russian Federation.
Comment type is not specified in the component properties.